WallStSmart
AIDX

20/20 Biolabs, Inc. Common Stock

NASDAQ: AIDX · HEALTHCARE · MEDICAL DEVICES

$1.49
-1.97% today

Updated 2026-05-05

Market cap
$15.62M
P/E ratio
P/S ratio
7.64x
EPS (TTM)
$-0.36
Dividend yield
52W range
$1 – $50
Volume
0.2M

20/20 Biolabs, Inc. Common Stock (AIDX) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item2016201720182019202020212022202320242025
Revenue$427000.00$313207.00$277047.00$288300.00$2.33M$9.62M$11.06M$1.42M$1.75M$2.05B
Revenue growth (YoY)-26.6%-11.5%+4.1%+708.4%+312.9%+14.9%-87.1%+23.0%+116608.5%
Cost of revenue$256220.00$182275.00$217595.00$263917.00$1.45M$4.93M$5.94M$1.32M$1.39M$1.44B
Gross profit$170780.00$130932.00$59452.00$24383.00$877174.00$4.69M$5.12M$109138.00$360311.00$604.54M
Gross margin40.0%41.8%21.5%8.5%37.6%48.8%46.3%7.7%20.6%29.6%
R&D$424426.00$267063.00$234492.00$195041.00$338874.00$193368.00$120043.00$1.41M$1.26M$592.57M
SG&A$5.06M$4.76M$3.34M
Operating income$-2.23M$-1.28M$-1.47M$-2.47M$-2.03M$1.94M$1.68M$-6.36M$-5.66M$-3.33B
Operating margin-522.4%-408.4%-532.1%-855.8%-87.1%20.2%15.2%-446.6%-323.1%-162.9%
EBITDA$-2.21M$-1.27M$-1.44M$-2.42M$-1.97M$2.07M$1.97M$-6.19M$-5.53M$-3.33B
EBITDA margin-516.5%-405.0%-521.0%-840.6%-84.3%21.5%17.8%-434.9%-315.3%-162.9%
EBIT$-2.23M$-1.28M$-1.47M$-2.47M$-2.03M$1.94M$1.68M$-6.36M$-5.66M
Interest expense$9472.00$12930.00$15685.00$27915.00$12646.00$-156.21M
Income tax
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net income$-2.23M$-1.26M$-1.46M$-2.43M$-2.02M$2.07M$2.19M$-6.39M$-5.55M$-3.74B
Net income growth (YoY)+43.3%-15.7%-65.8%+16.6%+202.5%+5.6%-392.3%+13.1%-67245.9%
Profit margin-521.8%-403.6%-528.1%-841.3%-86.8%21.5%19.8%-448.7%-316.8%-182.8%